

- *Professor in Clinical Chemistry* at the Department of Medicine and at the Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
- *Director of Research, Education, Development and Innovation*, at the National and International Affairs and the Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden
- *Senior Consultant* at the Medical Unit of Endocrinology, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden

#### **Present National/International Scientific Roles and Offices**

- Healthcare Data Innovation Council (<https://healthdatainnovation.eu/the-council/>) 2022 -
- Karolinska Institutet Faculty Council. 2022 -
- Academic Coordinator for Karolinska University Hospital for the Brigham and Women's Hospital/Harvard Medical School MoU 2021 -
- David och Astrid Hageléns Foundation – Karolinska Institutet. 2019 -
- Karolinska University Hospital representative in the Research Lead and in the Policy Working of the European University Hospital Alliance (EUHA) 2020 -
- Board of Directors of CM Lerici Foundation, Stockholm, Sweden; 2020 -
- International Scientific Advisory Board of the Dutch Heart Foundation. 2019 -
- National Representative of the European Association for Predictive, Preventive & Personalized Medicine (EPMA) in Sweden 2019 -
- Academic Coordinator for Karolinska Institutet in the Network Medicine Institute and Alliance. 2018 -
- Scientific Committee of the Center E. Grossi Paoletti, University of Milano. 2016 -

#### **Education, Degrees, Titles**

- *Professor in Clinical Chemistry*. Karolinska Institutet, Sweden. 2012
- *Associate Professor in Gastroenterology and Hepatology*. Karolinska Institutet, Stockholm, Sweden. 2007
- *Philosophy Doctor in Internal Medicine*. Karolinska Institutet, Sweden. 1994-1999
- *Medical Doctor* (110/110 cum laude). University of Bologna, Italy. 1983-1990

#### **Post-doctoral activities**

- *Dr. Lawrence L Rudel's Group*, Dept. of Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA, Oct. 2002 – Feb. 2003. and Nov 2004 – Apr. 2005
- *Metabolism Unit*, Dept. of Medicine, Huddinge University Hospital, and Molecular Nutrition Group, Centrum for Nutrition and Toxicology, Novum, Karolinska Institutet, Sweden, June 1999 – Sept. 2002 and Mars 2003 – Oct. 2004

#### **Continuing Professional Development**

##### Leadership and innovation

- “2020 Wave – The Lexicon of Empathy”; International Leadership Community@Your Business Partner, Italy
- “2019 Wave – The Garden of Empathy”; International Leadership Community@Your Business Partner, Italy
- “2018 Wave – Looking at Reality”; International Leadership Community@Your Business Partner, Italy
- “TUFF Leadership Training – Step 2”, 2017, Tuff ledarskapsträning AB, Sweden
- “TUFF Leadership Training – Step 1”; 2016, Tuff ledarskapsträning AB, Sweden
- “Project Leadership for Research Leaders (PLRL)”; 2013, Karolinska Institutet, Sweden
- “Development of leadership and teams”; 2011, Karolinska Institutet, Sweden
- “The personal leadership”; 2010, Karolinska Institutet, Sweden
- “UGL: development of groups and leaderships”; 2001, The Swedish Military Academy, Sweden

### Working-environment and regulatory guidelines

- “*Good Clinical Practice (GCP) for investigators*”; 2004, the Swedish Acad of Pharmac Sciences, Sweden
- “*Introductory course on internal control*”; 1998, Arbetskyddsmyndigheten, Sweden
- “*Introductory course on working-environment*”; 1998, Karolinska Institutet, Sweden
- “*Planning of Clinical Trials*”; 1997, Karolinska Institutet, Sweden

### **National Boards and Specializations**

- Authorization to practice the medical profession in Italy, 1990
- Specialization in Gastroenterology in Italy, 1994
- Authorization to practice the medical profession in Sweden, 1995
- Specialization in Gastroenterology in Sweden, 1995
- Specialization in Clinical Chemistry, 2012

### **Memberships to Scientific Societies**

- European Atherosclerosis Society; - The Scandinavian Arteriosclerosis Society; - The International Atherosclerosis Society
- The European Lipoprotein Club;

### **Past National/International Scientific Roles and Offices**

- *Visiting Professor*, Division of Cardiovascular Medicine, Dept of Medicine, at Brigham and Women's Hospital and at Harvard Medical School, Boston, USA, 2022-2023
- Scientific Advisory Board of DIACCURATE SAS, Paris, 2021 -2022
- Executive Committee the European Atherosclerosis Society. 2018 – 2021
- Chair of the Scientific Program Committee of the 89<sup>th</sup> EAS Congress Helsinki, 2021
- Swedish representative in the Scandinavian Society for Atherosclerosis Research (SSAR). 2008 – 2021
- Visiting Professor, Department of Pharmacological and Biomolecular Sciences, University of Milano. 2017 – 2019
- Swedish representative in the European Lipoprotein Club Organizing Committee (ELC), 2005-2010

### **Commercialization experience**

- CEO and Founder of Lipoprotein Research Stockholm AB, Sweden 2020 -
- Board of the Italian Chamber of Commerce in Sweden. 2017 -

### **Editorial Boards**

- Associate Editor of Frontiers in Cardiovascular Medicine, 2023
- Editorial board of Biology. 2019 –
- Associate Editor of Atherosclerosis. 2018 –
- Associate Editor of JEPMA. 2018 –
- Editorial board of Cell Transplantation. 2011-

### **Previous Leadership Roles**

- Treasurer of the European Atherosclerosis Society. 2018 – 2021
- FoU-Chef, Tema Inflammation and Infection, Karolinska University Hospital 2017 - 2020
- Coordinator of the EU project HUMAN (EU FP7 no 602757, [www.fp7human.eu/](http://www.fp7human.eu/), 12 MEuro)
- Head of the Division of Clinical Chemistry, Dept of Laboratory Medicine, Karolinska Institutet, 2010-2015
- Chairman of the Scandinavian Society for Atherosclerosis Research (SSAR), 2011-2015

### **Post-graduate Supervision**

PhD Main supervisor : 1) *Camilla Pramfalk*, “Regulation of the hepatic ACAT2 expression and roles of HNF1 and HNF in cholesterol metabolism” 27/11/2009; 2) *Lisa-Mari Nilsson*, ”Studies on cholesterol homeostasis by modulation of lipoproteins and bile acids” 29/01/2010; 3) *Treska Hassan*, “The oxysterol receptor-LXR:s: a link between inflammation and cancer” 10/ 2016; 4) *Osman Ahmen*, ” Studies on cholesterol homeostasis in the regulation of liver steatosis and insulin sensitivity ” 05 2019. 5) *Karin Littmann*, “Etablering av nya diagnostiska markörer för kardiometabola och pankreatiska sjukdomar. 5/2020; 6) *Mirko Minniti*, “Targeting cardiometabolic diseases: validation of new experimental models and therapeutic approaches”. 6/2020

PhD Co-supervisor: 1) *Manuela Matasconi*, Sep 2004 - Dec 2005; 2) *Katharina Slätis*, Jun 2002 – Apr 2009; 3) *Zhao-Yen Jiang*, 2007 – 2010; 4) *Xiao-Li Hu*, Ma 2009 – 2014; 5) *Alice Felici*, Oct 2019 – ongoing

Postdoc supervision: 1) *Matteo Pedrelli*, 2009-2014; 2) *Lisa-Mari Nilsson*, 2011-2014; 2) *Camilla Pramfalk*, 2009-2015; 3) *Davide Gnocchi*, 2013-2015; 5) *Tomas Jacobsson*, 2015-2016; 6) *Lise-Lotte Vedin*, 2015-2018

### **Awards and Honours**

### Scientific

- *Nikkilä Memorial Lecture Award, Scandinavian Society for Atherosclerosis Research, 2024*
- *Alvarenga's Prize, The Swedish Medical Society, 1996*

### Other

- *Paul Harris Fellow, Rotary International, 2020; - Livio Minguzzi Prize, Rotary Rimini, Italy, 2020; - Best book of the Year, Gourmand World Cookbook Awards, 2015; - Officer, Order of Merit of the Italian Republic, 2011*

### **Patents**

- *WO2021153570A1 (JP7430869B2) – Proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitor and pharmaceutical use therefor*

### **Major Research Grants Awarded in Competition 2023-2012**

- 2024 dAlbetes, Horizon 2023, European Union, Participating PI (7290000SEK)
- 2023 Internationellt strategiskt samarbete KI/KUH och MGB/HMS samt KTH, VINNOVA PI (1000000SEK)
- 2022 RePo4EU, Horizon 2022, European Union, Participating PI (4300000SEK)
- 2021-2019, Dissect (20210622; 20200668; 20190544), Swedish Heart Lung Foundation, PI (400000 SEK; 500000 SEK; 600000 SEK)
- 2020, Finding novel causes .... (20200736), Swedish Heart Lung Foundation Co-PI (3900000 SEK)
- 2017, Mechanisms and treatment ....., (20170830), Swedish Heart Lung Foundation, Co-PI (5000000 SEK)
- 2017-2016 Mekanismer bakom Rev ....., (20170487; 20160667), Swedish Heart Lung Foundation Co-PI (400000 SEK; 400000 SEK)
- 2016, Soat2 and Fsp27/CIDEC... (2016-02992), Swedish Research Council PI (2800000 SEK)  
Project on understanding the role of cholesterol esterification in cardiometabolic diseases
- 2016, Chronic kidney Disease ....., (20160384) Swedish Heart Lung Foundation, Co-PI (900000 SEK)
- 2015, Finding new causes ..., (20150470), Swedish Heart Lung Foundation, Co-PI (800000 SEK)
- 2013, Human, Swedish Research Council, PI Partner (3400000 SEK)
- 2013, Human, (20130370), EU FP7, PI Partner 1c and consortium coordinator (15437000 SEK)
- 2012, Swedish Research Council, PI (1800000 SEK)

### **Grant/Project/Position Evaluator 2012-2024**

- 2012, Research Grant, FWF, Der Wissenschaftsfond, Austria
- 2015, Diabetes Fond Yuniior Fellowships, Diabetes Fond, Holland
- 2019 - ongoing, International Scientific Advisory Committee - Dutch Heart Foundation, Holland
- 2020, Open Discovery Innovation Network (ODIN), Århus University, Denmark
- 2021, PRIN Program. Italian Minister for Research and University, Italy
- 2021, Applied and Engineering Sciences, NWO – Dutch Research Council, Holland
- 2021-2022, Grant Review Panel, Swedish Heart-Lung Foundation, Sweden
- 2022 - PPP Program Immunology, The Association of Collaborating Health Foundations (SGF) and Top Sector Life Sciences and Health (LSH), Holland
- 2022, PRRN - “Strengthening and creating Research Infrastructures” Program, Italian Minister for Research and University, Italy
- 2023, Grant Review, Agence National de la Recherche, France
- 2023, Grant Review Panel, Academy of Finland, Finland
- 2024. PPP Program Immunology, The Association of Collaborating Health Foundations (SGF) and Top Sector Life Sciences and Health (LSH), Holland
- 2024, Dutch Research Council (NOW) “Open Competition” Programme, Holland
- 2024, Dutch Research Council (NOW)-Dutch Heart foundation “Together for a better life with inherited heart disease”, Holland

### **Bibliometric Parameters**

- *Original peer-reviewed articles: 124*
- *Review articles, editorials, chapters in text-books, and proceedings: 50*
- *H-Index 54, i10-index 125, Citation 12272 (Google Scholar)*
- *Popular scientific books: 1 (> 15000 copies)*